Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.
| Revenue (TTM) | $1.08M |
| Gross Profit (TTM) | $-26.48M |
| EBITDA | $-68.94M |
| Operating Margin | -6571.00% |
| Return on Equity | -29.60% |
| Return on Assets | -22.30% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $5.91 |
| Price-to-Book | 3.86 |
| Price-to-Sales (TTM) | 397.30 |
| EV/Revenue | 2.926 |
| EV/EBITDA | 0.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 83655.00% |
| Shares Outstanding | $266.14M |
| Float | $33.90M |
| % Insiders | 18.08% |
| % Institutions | 64.64% |
Volatility is currently contracting
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 25,420 American Depositary Shares and 87,530 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 13 employees pursuant to the Company's 2025 Inducement Plan.
LONDON and GAITHERSBURG, Md., June 25, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will participate in the H.C.
LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product.
After losing some value lately, a hammer chart pattern has been formed for Autolus Therapeutics (AUTL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Autolus Therapeutics PLC Sponsored ADR (AUTL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AUTL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences.
Autolus Therapeutics NASDAQ: AUTL reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year revenue guidance for the cell therapy.
AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UK Company achieves positive gross margin for the acute lymphoblastic leukemia (ALL) business Cost reduction initiative to drive gross profit margin improvement and path to profitability for the ALL business underway Obe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS) Conference call to be held today at 8:30am EDT/1:30pm BST: conference call participants should pre-register using the link at the bottom of this press release LONDON and GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announces its operational and financial results for the first quarter ended March 31, 2026.
LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its first quarter 2026 financial results and operational highlights before open of U.S. markets on Thursday, May 14, 2026.
